141 related articles for article (PubMed ID: 34494462)
1. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
[TBL] [Abstract][Full Text] [Related]
2. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
5. Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2-/- (TRUC) mice.
Ermann J; Staton T; Glickman JN; de Waal Malefyt R; Glimcher LH
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):E2559-66. PubMed ID: 24927559
[TBL] [Abstract][Full Text] [Related]
6. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.
Cavallari JF; Barra NG; Foley KP; Lee A; Duggan BM; Henriksbo BD; Anhê FF; Ashkar AA; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E579-E585. PubMed ID: 32101030
[TBL] [Abstract][Full Text] [Related]
7. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
Schwerd T; Pandey S; Yang HT; Bagola K; Jameson E; Jung J; Lachmann RH; Shah N; Patel SY; Booth C; Runz H; Düker G; Bettels R; Rohrbach M; Kugathasan S; Chapel H; Keshav S; Elkadri A; Platt N; Muise AM; Koletzko S; Xavier RJ; Marquardt T; Powrie F; Wraith JE; Gyrd-Hansen M; Platt FM; Uhlig HH
Gut; 2017 Jun; 66(6):1060-1073. PubMed ID: 26953272
[TBL] [Abstract][Full Text] [Related]
8. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.
Nikhar S; Siokas I; Schlicher L; Lee S; Gyrd-Hansen M; Degterev A; Cuny GD
Eur J Med Chem; 2021 Apr; 215():113252. PubMed ID: 33601309
[TBL] [Abstract][Full Text] [Related]
9. RIPK2 NODs to XIAP and IBD.
Topal Y; Gyrd-Hansen M
Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Lechner K; Mott S; Al-Saifi R; Knipfer L; Wirtz S; Atreya R; Vieth M; Rath T; Fraass T; Winter Z; August A; Luban J; Zimmermann VS; Weigmann B; Neurath MF
Gastroenterology; 2021 Oct; 161(4):1270-1287.e19. PubMed ID: 34224738
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening.
Cruz JV; Neto MFA; Silva LB; da S Ramos R; da S Costa J; Brasil DSB; Lobato CC; da Costa GV; Bittencourt JAHM; da Silva CHTP; Leite FHA; Santos CBR
Molecules; 2018 Feb; 23(2):. PubMed ID: 29463017
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease.
Lai Y; Wang X; Sun X; Wu S; Chen X; Yang C; Zhang W; Yu X; Tong Y; Ma F; Zheng H; Zhang X; He S
Biochem Pharmacol; 2023 Aug; 214():115647. PubMed ID: 37315817
[TBL] [Abstract][Full Text] [Related]
13. Enterocyte dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin expression in inflammatory bowel disease.
Zeng JQ; Xu CD; Zhou T; Wu J; Lin K; Liu W; Wang XQ
World J Gastroenterol; 2015 Jan; 21(1):187-95. PubMed ID: 25574091
[TBL] [Abstract][Full Text] [Related]
14. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
Mares A; Miah AH; Smith IED; Rackham M; Thawani AR; Cryan J; Haile PA; Votta BJ; Beal AM; Capriotti C; Reilly MA; Fisher DT; Zinn N; Bantscheff M; MacDonald TT; Vossenkamper A; Dace P; Churcher I; Benowitz AB; Watt G; Denyer J; Scott-Stevens P; Harling JD
Commun Biol; 2020 Mar; 3(1):140. PubMed ID: 32198438
[TBL] [Abstract][Full Text] [Related]
15. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Duggan BM; Cavallari JF; Foley KP; Barra NG; Schertzer JD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32473019
[TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of Novel Receptor-Interacting Serine/Threonine-Protein Kinase 2 Inhibitors Using Structural Similarity Analysis.
Salla M; Aguayo-Ortiz R; Danmaliki GI; Zare A; Said A; Moore J; Pandya V; Manaloor R; Fong S; Blankstein AR; Gibson SB; Garcia LR; Meier P; Bhullar KS; Hubbard BP; Fiteh Y; Vliagoftis H; Goping IS; Brocks D; Hwang P; Velázquez-Martínez CA; Baksh S
J Pharmacol Exp Ther; 2018 May; 365(2):354-367. PubMed ID: 29555876
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
[TBL] [Abstract][Full Text] [Related]
18. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Larabi A; Barnich N; Nguyen HTT
Autophagy; 2020 Jan; 16(1):38-51. PubMed ID: 31286804
[TBL] [Abstract][Full Text] [Related]
19. A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.
Heim VJ; Dagley LF; Stafford CA; Hansen FM; Clayer E; Bankovacki A; Webb AI; Lucet IS; Silke J; Nachbur U
EMBO Rep; 2020 Nov; 21(11):e50400. PubMed ID: 32954645
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
